Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients.
Eugenio De CorsoDavide Paolo PorruMarco CorbòClaudio MontuoriGabriele De MaioRodolfo Francesco MastrapasquaMarco PanfiliCamilla SpanuGiuseppe Alberto Di BellaGiuseppe D'AgostinoAlberta RizzutiGiulio Cesare PassaliJacopo GalliPublished in: Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery (2024)
Both dupilumab and ESS were effective in improving outcomes in patients with severe CRSwNP over 12 months. Nevertheless, patients treated with dupilumab had greater improvement in terms of SNOT-22, VAS rhinorrhoea, VAS smell and SSIT scores, with better control of local inflammation and less need for OCS.
Keyphrases
- atopic dermatitis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- early onset
- ejection fraction
- minimally invasive
- oxidative stress
- peritoneal dialysis
- coronary artery bypass
- coronary artery disease
- drug induced
- percutaneous coronary intervention
- insulin resistance
- replacement therapy
- smoking cessation